发明名称 PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF
摘要 This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients.
申请公布号 US2015366915(A1) 申请公布日期 2015.12.24
申请号 US201514713108 申请日期 2015.05.15
申请人 Ocata Therapeutics, Inc. 发明人 Gay Roger;Klimanskaya Irina V.;Lanza Robert P.
分类号 A61K35/30;A61K31/4409 主分类号 A61K35/30
代理机构 代理人
主权项 1. A cell culture comprising human RPE cells and cell culture media including a rho-associated protein kinase (ROCK) inhibitor.
地址 Marlborough MA US